Predict your next investment

Corporation
bio-techne.com

See what CB Insights has to offer

Investments

6

Portfolio Exits

2

Partners & Customers

10

Service Providers

1

About Bio-Techne

Techne Corporation, dba Bio-Techne, (NASDAQ: TECH), is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

Bio-Techne Headquarters Location

614 McKinley Place NE

Minneapolis, Minnesota, 55413,

United States

612-379-2956

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bio-Techne

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Bio-Techne in 1 Expert Collection, including Cancer.

C

Cancer

105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

Latest Bio-Techne News

Bio-Techne is Our Growth Stock of the Week

Aug 12, 2022

It's uncertain whether the current market advance is the start of a new bull market or a bear market rally. What cannot be debated is that biotech stocks are leading... This story originally appeared on StockNews It's uncertain whether the current market advance is the start of a new bull market or a bear market rally. What cannot be debated is that biotech stocks are leading the market higher. Since the June lows, the iShares Biotechnology Index (IBB) is up 29%, nearly double that of the S&P 500. Among biotech stocks, investors should target fundamentally strong companies with powerful catalysts. That is why I want to talk about a biotech - Bio-Techne (TECH) - with major upside and all the characteristics of a market leader in today's article. shutterstock.com - StockNews The stock market is in the midst of an impressive and massive bear market rally. Since the low on June 17, the S&P 500 is up nearly 16%. Some of the major catalysts behind the rally are an unwinding of extreme levels of bearish sentiment, better than expected economic data, and marginal progress on the inflation front. Of course, there is a lively debate about whether this is a new bull market or a bear market rally that will inevitably roll over. What cannot be debated is that biotech stocks are leading the market higher. Since the June lows, the iShares Biotechnology Index ( IBB ) is up 29%, nearly double that of the S&P 500. The sector also made a double bottom in June with the May lows, while the broader market made a lower low. Among biotech stocks, investors should target fundamentally strong companies with powerful catalysts. That is why I want to talk about a biotech stock - Bio-Techne ( TECH ) - with major upside and all the characteristics of a market leader in today's article. Background TECH is a supplier and manufacturer of biological materials like high-quality purified proteins and reagents like cytokines, growth factors, and antibodies that are used by pharmaceutical and biotech companies for their drug development and testing processes, specifically for genetic and cellular-based therapies. In addition to this, it also provides instruments and custom manufacturing solutions. Thus, TECH provides investors with exposure to the genomics industry which is expected to grow at a 19.8% rate over the next decade. As a supplier to the industry, it has less risk than investing in the companies using genomics to develop drugs and bring them to market. GARP Every stock market strategy has its day in the sun. I believe this is a time when GARP investors are going to see stunning returns. For one, growth stocks have been mired in a brutal bear market for more than a year. Second, bearish headwinds in the form of rising inflation and long-term rates have ameliorated which means that investors need to start targeting, high-quality companies especially ones that are growing earnings. TECH certainly has strong growth characteristics given that earnings are expected to double over the next year. Its recent earnings report showed a 17% increase in revenue. Unlike most companies, it's also seeing operating margins expand. While TECH is certainly not cheap on a forward valuation basis with a P/E of 39, it's quite cheap when pricing in its long-term growth rate, attractive business model, and growth of the overall industry. Catalysts For the full year, analysts are forecasting $7.95 in EPS and $1.1 billion in revenue which would be improvements of 17% and 18%, respectively. The company has a good mix of slow and steady growth from its older reagent business with strong growth, albeit from a small base, in its genetic and cell therapy products. On a longer-term basis, biotech stocks are one of the few areas of the market offering good value. This is evident in that about 40% of small and mid-cap biotech stocks have more cash on their balance sheets than their market cap. The longer-term bull case remains intact as the cost of drug development continues to decline, and the aging population means that the demand for new treatments will only continue to increase. POWR Ratings As for the POWR Ratings, TECH is rated a Buy. It has a B grade for Sentiment as the Wall Street analyst community is very bullish on the stock with 5 out of 6 having a Buy rating with a consensus price target implying 30% upside. It also has a Quality grade of B due to a strong balance sheet and returning cash to shareholders through dividends and buybacks while staying on a growth trajectory. Click here to access Bio-Techne's (TECH) full POWR ratings.

Bio-Techne Investments

6 Investments

Bio-Techne has made 6 investments. Their latest investment was in Eminence as part of their Corporate Minority on January 1, 2021.

CBI Logo

Bio-Techne Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/28/2021

Corporate Minority

Eminence

Yes

1

12/15/2016

Series F

Subscribe to see more

$99M

Subscribe to see more

10

5/4/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

4/4/2014

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

6/16/2006

Series C

Subscribe to see more

$99M

Subscribe to see more

0

Date

1/28/2021

12/15/2016

5/4/2016

4/4/2014

6/16/2006

Round

Corporate Minority

Series F

Series A

Corporate Minority

Series C

Company

Eminence

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

0

Bio-Techne Portfolio Exits

2 Portfolio Exits

Bio-Techne has 2 portfolio exits. Their latest portfolio exit was Astute Medical on April 04, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/4/2018

Acquired

$99M

3

2/8/2012

IPO

Subscribe to see more

$99M

Subscribe to see more

0

Date

4/4/2018

2/8/2012

Exit

Acquired

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

3

0

Bio-Techne Acquisitions

16 Acquisitions

Bio-Techne acquired 16 companies. Their latest acquisition was Namocell on June 22, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/22/2022

$99M

Acquired

3

3/3/2021

Debt

$99M

$88.34M

Acquired

6

6/5/2019

Series A

$99M

$1M

Acquired

1

6/25/2018

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

6/7/2018

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

6/22/2022

3/3/2021

6/5/2019

6/25/2018

6/7/2018

Investment Stage

Debt

Series A

Series C

Series A

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$88.34M

$1M

$99M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

3

6

1

10

10

Bio-Techne Partners & Customers

10 Partners and customers

Bio-Techne has 10 strategic partners and customers. Bio-Techne recently partnered with University of Dundee on July 7, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

7/28/2022

Licensor

United Kingdom

Bio-Techne Licenses Protein Degradation Technology From University of Dundee

NEW YORK -- Bio-Techne said on Thursday that it has exclusively licensed a technology for identifying protein-based drug targets from the University of Dundee .

1

5/12/2022

Licensor

United States

07:00 EDT Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test

MINNEAPOLIS and LOS ANGELES , May 12 , 2022 / PRNewswire / -- Bio-Techne Corporation and Nonagen Bioscience today announced an agreement for R&D Systems , a Bio-Techne Corporation brand , to exclusively manufacture Nonagen Bioscience 's Oncuria ® bladder cancer diagnostic panel using xMAP Luminex ® technology .

1

2/22/2022

Licensee

United States

2

1/5/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

1/5/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

7/28/2022

5/12/2022

2/22/2022

1/5/2022

1/5/2022

Type

Licensor

Licensor

Licensee

Partner

Partner

Business Partner

Country

United Kingdom

United States

United States

United States

United States

News Snippet

Bio-Techne Licenses Protein Degradation Technology From University of Dundee

NEW YORK -- Bio-Techne said on Thursday that it has exclusively licensed a technology for identifying protein-based drug targets from the University of Dundee .

07:00 EDT Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test

MINNEAPOLIS and LOS ANGELES , May 12 , 2022 / PRNewswire / -- Bio-Techne Corporation and Nonagen Bioscience today announced an agreement for R&D Systems , a Bio-Techne Corporation brand , to exclusively manufacture Nonagen Bioscience 's Oncuria ® bladder cancer diagnostic panel using xMAP Luminex ® technology .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Bio-Techne Service Providers

1 Service Provider

Bio-Techne has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Counsel

General Counsel

Service Provider

Associated Rounds

Acquired

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Bio-Techne Team

5 Team Members

Bio-Techne has 5 team members, including current President, Kim Kelderman.

Name

Work History

Title

Status

Kim Kelderman

President

Current

Greg Melsen

Chief Executive Officer, Chief Financial Officer

Former

Yuling Luo

President

Former

Steven Chen

Chief Operating Officer

Former

Matthew F McManus

Senior Vice President

Former

Name

Kim Kelderman

Greg Melsen

Yuling Luo

Steven Chen

Matthew F McManus

Work History

Title

President

Chief Executive Officer, Chief Financial Officer

President

Chief Operating Officer

Senior Vice President

Status

Current

Former

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.